A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane ‐based regimens

ConclusionIn Japanese MBC patients in a real‐world setting, eribulin showed a survival benefit and tolerability similar to that in previous reports.

Source: Asia-Pacific Journal of Clinical Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Yasuko Kikuchi, Yoshihiro Uchida, Kazuo Shirakawa, Hajime Kanauchi, Takayoshi Niwa, Kotoe Nishioka, Keiichirou Tada, Masanori Hashimoto, Hidemitsu Yasuda, Ryoko Sugiura, Hidetaka Kawabata, Yasuyuki Seto, Toshihisa Ogawa Tags: ORIGINAL ARTICLE Source Type: research